Biotechnology to improve health in developing countries - A review

Memorias do Instituto Oswaldo Cruz

Volumn 99, Issue 4, 2004, Pages 341-350

  Acharya, Tara ^a   Kennedy, Robyn ^a   Daar, Abdallah S ^a   Singer, Peter A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biotechnology; Developing countries; Global health

Indexed keywords

BCG VACCINE; DNA VACCINE; HEPATITIS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; SMALLPOX VACCINE; VIRUS VACCINE;

BIOMEDICINE; BIOTECHNOLOGICAL PROCEDURES; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DIAGNOSTIC PROCEDURE; GENOMICS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; NONHUMAN; PUBLIC HEALTH SERVICE; REVIEW; SEXUALLY TRANSMITTED DISEASE; SMALLPOX; TUBERCULOSIS; VIRUS INFECTION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM BOVIS BCG; VARIOLA VIRUS;

EID: 3242680777     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762004000400001     Document Type: Review

References (74)

1. Acharya T, Daar AS, Singer PA 2003. Biotechnology and the UN's Millennium Development Goals. Nat Biotechnol 21: 1434-1436.
2. Adler M, Ziglio E 1996. Gazing into the Oracle: The Delphi Method and its Implications to Social Policy and Public Health, Jessica Kingsley Publishers, London.
3. Anopheles Database. http://skonops.imbb.forth.gr/AnoBase/
4. Bakker H, Bardor M, Molthoff JW, Gomord V, Elbers I, Stevens LH, Jordi W, Lommen A, Faye L, Lerouge P, Bosch D 2001. Galactose-extended glycans of antibodies produced by transgenic plants. Proc Natl Acad Sci 98: 2899-2904.
5. Balter M 2001. Malarial research: sequencing set for dreaded mosquito. Science 291: 1873.
6. Blakeslee D 1998. Blocking HIV transmission the natural way: 2 new ideas. JAMA HIV/AIDS Information Centre Special Report.
7. Bojang KLA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, RTS, S Malaria Vaccine Trial Team 2001. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358: 1927-1934.
8. Boyd MD 1997. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds vival surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 41: 1521-1530.
9. Breekveldt J, Jongerden J 1998. Transgenic animals in pharmaceutical production. Biotechnol Dev Monitor 36: 19-22.
10. Brumfiel G 2004 Cell Biology: just add water. Nature 428: 14-15.
11. Carol AN, Sacksteder KA 2002. New tuberculosis vaccine development. Expert Opinion on Biological Therapy 2: 741-749.
12. Chakraborty S, Charaborty N, Datta A 2000. Increased nutritive value of transgenic potato by expressing a nonallergenic seed of albumin gene from Amaranthus hypochodriaccus. Proc Natl Acad Sci USA 97: 3724-3729.
13. Coghlan A 2003. 'Protato' to feed India's poor. New Scientist 177: 7.
14. Coler RN, Campos-Neto A, Ovendale P, Day FH, Fling SP, Zhu L, Serbina N, Flynn JL, Reed SG, Alderson MR 2001. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol 166: 6227-6235.
15. Commission on the Private Sector & Development 2004. Unleashing Entrepreneurship Entrepreneurship: Making Business Work for the Poor, United Nations, New York, NY.
16. Corseuil HX, Moreno FN 2001. Phytoremediation potential of willows trees for aquifers contaminated with ethanol-blended gasoline. Water Res 35: 3013-3017
17. Cowman A 2001. Functional analysis of drug resistance in Plasmodium falciparum in the post-genomic era. Int J Parasitol 31: 871-878.
18. Daar AS, Thorsteinsdóttir H, Martin DK, Smith AC, Nast S, Singer PA 2002. Top 10 biotechnologies for improving health in developing countries. Nat Gen 32: 229-232.
19. Express Pharmapulse 2003. http: www.expresspharmapulse. com/story.php?&idno=206
20. Fletcher MA 2001. Vaccine candidates in STD. Int J STD AIDS 12: 419-422.
21. GenBank www.ncbi.nih.gov/genbank
22. Grandi G 2001. Antibacterial vaccine design using genomics and proteomics. Trends Biotech 19: 181-188.
23. Grandi G 2003. Rational antibacterial vaccine design through genomic technologies. Review. Int J Parasitol 5-6: 615-620.
24. Graven A, St Hilaire PM, Sanderson SJ, Mottram JC, Coombs GH, Meldal M 2001. Combinatorial library of peptide isosters based on Diels-Alder reactions: identification of novel inhibitors against a recombinant cysteine protease from Leishmania mexicana. J Comb Chem 3: 441-452.
25. Harris E, Kropp G, Belli A, Rodriguez B, Agabian N 1998. Single-step multiplex PCR assay for characterization of New World Leishmania complexes. J Clin Microbiol 36: 1989-1995.
26. Hoekstra WJ, Maryanoff BE, Damiano BP, Andrade-Gordon P, Cohen JH, Costanzo MJ, Haertlein BJ, Hecker LR, Hulshizer BL, Kauffman JA, Keane P, McComsey DF, Mitchell JA, Scott L, Shah RD, Yabut SC 1999. Potent, orally available GPIIb/Iia antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem 42: 5254-5265.
27. International AIDS Vaccine Initiative. http://www.iavi.org/ iavireport/0103/trialswatch.htm
28. Jain AK, Nessler CK 2000. Metabolic engineering of an alternative pathway for ascorbic acid biosynthesis in plants. Molecular Breeding 6: 73-78.
29. Jomaa H, Wiesner J, Sanderbrand S, Altincicek B, Weidemeyer C, Hintz M, Turbachova I, Eberl M, Zeidler J, Lichtenthaler HK, Soldati D, Beck E 1999. Inhibitors of the nonmavalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285: 1573-1576.
30. Korkusuz F, Korkusuz P, Eksioglu F, Gursel I, Hasirci V 2001. In vivo response to biodegradable controlled antibiotic release systems. J Biomed Mater Res 55: 217-228.
31. Lehmann V 1998. Bioremediation: a solution for polluted soils in the South? Biotech and Dev Monitor 34: 12-17.
32. Lloyd J 2000. Technologies for vaccine delivery in the 21st century. WHO, Geneva, http://www.who.int/vaccines-documents/DocsPDF00/www554.pdf
33. Loferer H 2000. Mining bacterial genomes for antimicrobial targets. Review. Mol Med Today 6: 470-474.
34. Louie M, Louie L, Simor AE 2000. The role of DNA amplification technology in the diagnosis of infectious disease. CMAJ 163: 301-309.
35. Lundvall BA 1992. National System of Innovation: Toward a Theory of Innovation and Interactive Learning, Pinter Publishers, London.
36. Lyall A 1996. Bioinformatics in the pharmaceutical industry. Trends Biotech 14: 308-312.
37. Ma LQ, Komar KM, Tu C, Zhang W, Cai Y, Kennelley ED 2001. A fern that hyperaccumulates arsenic. Nature 409: 579.
38. Miertus S, Fassina G 1999. Combinatorial Chemistry and Technology, Marcel Dekker Inc, New York.
39. Molecular Modeling Database (MMDB). www.ncbi.nih.gov/ structure
40. Moynihan JS, Blair J, Coombes A, D'Mello F, Howard CR 2002. Enhanced immunogenicity of a hepatitis B virus peptide vaccine using oligosaccharide ester derivative microparticles. Vaccine 20: 1870-1876.
41. Nicolaou KC, Namoto K, Li J, Ritzen A, Ulven T, Shoji M, Zaharevitz D, Gussio R, Sackett DL, Ward RD, Hensler A, Fojo T, Giannakakou P 2001. Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis. Chemistry 7: 3824-3843.
42. Ocean Arks International. http://www.oceanarks.org/about/intro/
43. Oduola A, Wayling S, Morel C 2002. Genomics and bioinformatics for tropical diseases. TDR Newsletter 68. http://www.who.int/tdr/publications/ tdrnews/news68/ bioinformatics.htm.
44. OptiMAL. http://www.malariatest.com/.
45. Palmer CJ, Lindo JF, Klaskala WI, Quesada JA, Kaminsky R, Baum MK, Ager AL 1998. Evaluation of the OptiMAL test for rapid diagnosis of Plasmodium vivax and Plasmodium falciparum malaria. J Clin Microbiol 36: 203-206.
46. Park SJ, Taton TA, Mirkin CA 2002. Array-based electrical detection of DNA with nanoparticle probes. Science 295: 1503-1506.
47. PATH-Program for Applied Technology in Health. www. path.org
48. Pipeline Project. Table of Vaccine Trials. http://chi.ucsf.edu/ vaccines?page=vc-03-00.
49. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappuoli R 2000. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816-1820.
50. Population Council. http://www.popcouncil.org/biomed/ candidate.html.
51. Potrykus I 2001. Golden rice and beyond. Plant Physiol 125: 1157-1161.
52. Santini JM, Sly LI, Schnagl RD, Macy JM 2000. A new chemolithoautotrophic arsenite-oxidizing bacterium isolated from a gold mine: phylogenetic, physiological and preliminary biochemical studies. Appl Environ Micriobiol 66: 92-97.
53. Singer PA, Daar AS 2001. Harnessing genomics and biotechnology to improve global health equity. Science. 294: 87-89.
54. Singer MA, Lindquist S 1998. Thermotolerance in Saccharomyces cerevisiae: the Yin and Yang of trehalose. Trends Biotechnol 16: 460-468.
55. South African National Bioinformatics Institute (SANBI). http:/ /www.sanbi.ac.za/
56. S-star. http://s-star.org.
57. Swiss-Prot. http://ca/expasy.org/sprot/.
58. TDR (The Special Programme for Research and Training in Tropical Diseases). http://www.who.int/tdr/index.html.
59. UN Millennium Development Goals. http://www.un.org/ millenniumgoals/.
60. UNFPA 2001. Understanding the Causes of Maternal Deaths, Distance Learning Pilot Course.
61. Van De Wijgert J 2001. Phase 1 trial of the topical microbicide BufferGe1: safety results from four international sites. J Acquir Immune Defic Syndr 26: 21-27.
62. WHO 2000a. HIV, TB and Malaria - Three Major Infectious Disease Threats. http://www.who.int/inf-fs/en/ back001.html.
63. WHO 2000b. Press Release: 8 September. Researchers warn of impending disaster from mass arsenic poisoning. http:// www.who.int/inf-pr-2000/en/pr2000- 55.html.
64. WHO 2000c. Fact Sheet 249: Women and Sexually Transmitted Infections. http://www.who.int/inf-fs/en/fact249.html.
65. WHO 1998. Fact Sheet 178: Reducing mortality from major killers of children. http://www.who.int/inf-fs/en/ fact178.html.
66. WHO 2000. Fact Sheet 116: The Leishmaniases and Leishmania/HIV Co-infections. http://www.who.int/inf-fs/en/ fact116.html.
67. WHO 2001. Macroeconomics and Health: Investing in Health for Economic Development Report of the Commission on Macroeconomics and Health. http://www3.who.int/whosis/ menu.cfm?path=whosis,cmh&language=english.
68. WHO 2002. Fact Sheet 4: Roll Back Malaria: Malaria in Pregnancy. http://www.who.int/inf-fs/en/InformationSheet04. pdf.
69. WHO. Noncommunicable Disease Prevention and Health Promotion. http://www.who.int/hpr/ncd.facts.shtml
70. WHO. Nutrition. http://www.who.int/nut/nutrition2.htm.
71. Widdus R 1999. The potential to control or eradicate infectious diseases through immunisation. Vaccine 17: S6-12.
72. World Bank 1993. World Development Report 1993: Investing in Health, Oxford University Press, Oxford.
73. Ye X, Al-Babili S, Kloti A, Zhang J, Lucca P, Beyer P, Potrykus I 2000. Engineering the provitamin A (β-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Sciv ence 257: 303-305.
74. Zeitlin L, Cone RA, Whaley KJ 1999. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis 5: 54-64.